by The global Stem Cell Manufacturing Market is estimated to be valued at US$ 12415.84 Mn in 2023 and is expected to exhibit a CAGR of 13.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Stem cell manufacturing involves various processes that are used to grow and develop stem cells for research and therapeutic applications. Stem cell manufacturing facilitates isolation, purification, cryopreservation and characterization of stem cells. Some key steps in stem cell manufacturing include harvesting stem cells from tissues or blood, isolation and enrichment of stem cells, in vitro expansion or amplification of stem cells, characterization of stem cells and storage or banking of stem cells. Stem cell manufacturing is crucial for derivation of stem cells into clinical-grade therapeutic products for cell-based therapies and regenerative medicines. It helps ensure safety, identity, purity and potency of stem cells intended for human use. Rapidly growing stem cell therapies market is significantly driving the demand for stem cell manufacturing to deliver standardized, high quality and scalable stem cell production processes.
Market key trends:
One of the major trends in the stem cell manufacturing market is automation and closed cell processing systems. Manual and open processing systems carry higher risks of contamination and lack repeatability and scalability. Automated closed cell manufacturing platforms help overcome these challenges through robotics, single-use technologies and digitization of processes. This significantly improves product quality, increases throughput and reduces production costs. Other key trends include enhancement of stem cell expansion techniques, development of xeno-free and chemically defined culture media, incorporation of continuous bioprocessing technologies and increasing outsourcing of stem cell manufacturing activities to specialized contract manufacturing organizations (CMOs). These trends are expected to revolutionize stem cell therapies landscape and critical in advancing the field of regenerative medicine commercialization.
Porter’s Analysis
Threat of new entrants: Low capital requirements and established industry players make the entry of new players difficult in this market.
Bargaining power of buyers: Large buyers can negotiate lower prices due to the consolidated nature of the market.
Bargaining power of suppliers: A few large suppliers exist for crucial biomaterials and equipment required for manufacturing stem cells resulting in higher bargaining power.
Threat of new substitutes: Limited substitutes currently exist for stem cell therapy making this market less vulnerable to threats from substitutes.
Competitive rivalry: The presence of large multinational corporations has intensified the competitive rivalry in this market.
Key Takeaways
The Global Stem Cell Manufacturing Market Size is expected to witness high growth, exhibiting CAGR of 13.3% over the forecast period, due to increasing applications of stem cells in new therapeutic areas and product advancements.
The North America region is expected to dominate the global market owing to ongoing clinical trials and increasing investments in research and development. However, Asia Pacific is likely to exhibit the highest growth rate during the forecast period on account of rising stem cell banking facilities and growing medical tourism in the region.
Key players operating in the stem cell manufacturing market include TAKARA BIO Inc., PHARMICELL Co., Ltd., MEDIPOST Co., Holostem Terapie Avanzate S.r.l, Bio-Rad Laboratories, Anterogen Co., Ltd., Osiris Therapeutics, Inc., Minaris Regenerative Medicine, Nikon CeLL Innovation Co. Ltd., Medinet Co. Ltd., Cell and Gene Therapy Catapult, Bio Elpida, Miltenyi Biotec, Pluristem Therapeutics Inc., Thermo Fischer Scientific, Merck Group, Corning Incorporated, Stem Cell Technologies, Lonza Group, Becton, Dickinson and Company, Sartorius, and Cellular Dynamics among others.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
